Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)Adi Diab, Daniel C. Cho, Nizar M. Tannir et al.|Cancer Discovery|2020Cited by 239
A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid TumorsSalah-Eddine Bentebibel, Adi Diab, Michael E. Hurwitz et al.|Cancer Discovery|2019Cited by 233
Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematologic CancersPablo D. García, Matthew T. Burger, John L. Langowski et al.|Clinical Cancer Research|2014Cited by 111
NKTR-358: A novel regulatory T-cell stimulator that selectively stimulates expansion and suppressive function of regulatory T cells for the treatment of autoimmune and inflammatory diseasesNeha Dixit, Jonathan Zalevsky, Christie Fanton et al.|Journal of Translational Autoimmunity|2021Cited by 54
The regulatory T cell-selective interleukin-2 receptor agonist rezpegaldesleukin in the treatment of inflammatory skin diseases: two randomized, double-blind, placebo-controlled phase 1b trialsJonathan I. Silverberg, Jonathan Zalevsky, David Rosmarin et al.|Nature Communications|2024Cited by 37